CHEESY GÁRLIC
PÁRMESÁN SPINÁCH SPÁGHETTI SQUÁSH
This crázy
delicious gárlic pármesán spághetti
squásh is one of the most populár
recipes on Peás ánd Cráyons -- ánd for
good reáson too!
Ingredients
·
1 medium
spághetti squásh (ápprox. 2-3lbs)
·
2.5 TBSP minced gárlic
·
5 oz fresh
spinách chopped
·
1/2 cup heávy
creám
·
1 TBSP creám
cheese (optionál but delicious!)
·
1/2 cup freshly
gráted pármesán cheese plus extrá for topping
·
sált ánd pepper to táste
·
gráted or sliced mozzárellá for topping to táste
Instructions
1.
Pre-heát oven to 400 degrees F.
2.
Slice your spághetti squásh in hálf lengthwise ánd scoop out the
seeds.
3.
For eásy cutting, feel free to stick your squásh in the microwáve
to soften it up just á tád. Pierce it á few times with á knife (to help vent so
it doesn't burst) ánd cook for for 3-5 minutes. The knife slides through wáy eásier
this wáy! Smáller squásh will need ábout 3 minutes while lárger ones will be
good to go át 4-5 min.
4.
Next gráb á lipped báking sheet or á rimmed báking dish.
5.
Rub the cut side of the squásh with á teeny bit of olive oil ánd
pláce on your báking dish/sheet cut side down. Roást for ábout 40 minutes, or
until tender ánd eásily pierced with á fork. Cooking time will váry á bit
depending on the size of your squásh, ánd lárger squásh will need to roást á
bit longer to tenderize. Once reády, the once rock-hárd exterior of the squásh
will be visibly softened with á tender interior.
6.
The squásh cán be roásted ánd stored in the fridge for á few dáys
if you'd like to meál prep ánd plán áheád for á speedier dinner.
7.
While the squásh roásts, stárt on the sáuce.
8.
In á medium pot or skillet, bring á drizzle of olive oil to
medium-high heát ánd sáuté gárlic until frágránt.
9.
Next ádd the spinách ánd stir until wilted. Ádd your creám, creám
cheese (totálly optionál but totálly tásty) ánd pármesán cheese ánd stir well.
10.
Seáson with sált ánd pepper to táste ánd remove from heát.
11.
Once squásh is done roásting, állow to cool until eásily hándled
or pop on án oven mit ánd use á fork to sepáráte ánd fluff the stránds of spághetti
squásh.
12.
......
13.
...............
14.
......................
FULL INSTRUCTION : peasandcrayons.com
The debate may determine the future of health care policy in the United States. Nevertheless, pharmaceutical investors should be alert to potential downward price pressure, no matter the outcome on Capitol Hill.
Argument in Favor of Government Intervention
The Obama administration signed an executive order in January to limit the amount pharmaceutical companies can charge for drugs. By May, Congress began hearings on an overhaul of Medicare Part B to allow greater government control over pricing mechanisms. This would amount to a price ceiling on pharmaceutical products.
The turning point in the drug debate may have been the sudden spike in prices for Daraprim, a treatment for parasite infections, and cycloserine, which is designed to battle tuberculosis. The cost of Daraprim rose from $13.50 to $750 per tablet after being acquired by Turing Pharmaceuticals. Cycloserine jumped from $16.67 per tablet to $360 per tablet once Rodelis Therapeutics purchased its rights. Several other drugs, notably the antibiotic doxycycline, have experienced similar price increases since 2013.
Major news outlets, particularly the New York Times, expressed outrage at pharmaceutical companies and hedge fund financiers for exploiting sick people. Public outcry followed, and Congress spearheaded several investigations into corporate practices. There are legitimate concerns about whether pharmaceutical companies operate as de facto monopolies and are able to restrict supply to drive up prices.
Argument in Favor of Free-Market Principles
It is very difficult to prove the net effect of regulations. Economists cannot run trials before policy experiments. The best economics can do is highlight the most likely outcomes and then look for supporting evidence.
Fortunately, when viewed through this prism, the obvious conclusion – regulations and restrictions limit competition and harm consumers – receives support from the historical results. Using this logic, the government should do less to help lower drug costs, not more. Dean Baker, economist and the co-director of the Center for Economic and Policy Research, says the pharma industry "has all of the problems economics predicts when government interferes with the market."
The U.S. health care cost crisis did not exist before 1965. Until 1964, health care costs rose at nearly identical rates to the Consumer Price Index (CPI), according to U.S. Census Bureau data. Pharmaceutical research costs and drug prices rose an average of 3% between 1935 and 1965, barely above the 2.8% CPI for the same period.
Medicare and Medicaid were enacted in 1965, further removing consumers from the cost of their medications. Thereafter, doctors and hospitals were increasingly reimbursed through cost formulas and received fees for service instead of receiving income based on quality and results. This crippled the vital role of consumer discrimination against high costs or ineffective treatment.
Extreme limits on pharmaceutical competition make matters worse. in 1962 the Food and Drug Administration (FDA) enacted the Kefauver-Harris Amendment, making it much more difficult to receive approval for a new drug. In 1972, the Nixon administration passed laws forbidding the construction of new hospitals without a federal certificate of need. Research from RAND showed the cost of a day in the hospital increased approximately 1,000% between 1972 and 2012.
Prices Would Go Down If Competition Were Legal
It is practically impossible for new entrants to compete in the pharmaceutical industry. In 2003, the Tufts Center for the Study of Drug Development published a study in the Journal of Health Economics titled "The price of innovation: new estimates of drug development costs." It einsurance quote ireland,insurance 77015,insurance quotes florida,insurance quotes online,insurance quotes texas,insurance rates by car,insurance rates,insurance quote comparison,insurance comparison,insurance,insurance for new drivers,insurance quotes cheap,insurance companies,insurance ireland,insurance estimator,insurance groups,insurance xchange,insurance leads,insurance yuma az,insurance companies near me,insurance price check,insurance check,insurance lawyer,insurance risk,insurance 24,insurance land,insurance for a month,insurance yakima,insurance lapse,insurance journal,insurance agent,insurance king,insurance sales,insurance quote ontario,insurance premium,insurance logo,insurance works,insurance services,insurance rider,insurance calculator,insurance declaration page,insurance services office,insurance 6 months,insurance zip code,insurance meaning,insurance management,insurance 2 wheeler,insurance card,insurance excess,insurance usa,insurance broker,insurance nation,insurance one,insurance adjuster,insurance database,insurance hire car,insurance post,insurance two wheeler,insurance group 1 cars,insurance health card,insurance types,insurance news,insurance quote geico,insurance hound,insurance network,insurance in germany,insurance on the spot,insurance zone,insurance 101,insurance geico,insurance act,insurance underwriting process,insurance 321,insurance line,insurance 2 go,insurance market,insurance industry,insurance solutions,insurance marketplace,insurance history check,insurance insider,insurance specialist,insurance number,insurance 50/50,insurance deductible,insurance auto auction,insurance 365,insurance university,insurance 80/20,insurance zenith,insurance 7702,insurance noodle,insurance emporium,insurance endorsement,insurance europe,insurance verification,insurance 2018,insurance license,insurance zipcar,insurance training,insurance sales jobs,insurance green card,insurance jobs london,insurance 220 license,insurancewith,insurance product information document,insurance jobs manchester,insurance 21,insurance jobs near me,insurance 99223,insurance history,insurance exam,insurance 1st central,insurance 4 car hire review,insurance jobs,insurance test,insurance underwriter salary,insurance adjuster jobs,insurance in blackjack,insurance 4 car hire,assurance wireless,insurance 80/20 rule,insurance companies in japan,insurance ombudsman,insurance jobs in dubai,insurance 360,insurance 02,insurance 0800,insurance 10e,insurance 11e,insurance 125cc,insurance 3rd party bike,insurance 4 my caravan,insurance 4 sport,insurance 5,insurance 5 years,insurance 5000,insurance 6 points,insurance 7,insurance 79936,insurance 7e,insurance 8e,insurance 8th street,insurance 9,insurance 90 day waiting period,insurance 94,insurance 9e,insurance act 2015,insurance age,insurance as a service,insurance development forum,insurance factory,insurance for foreigners in japan,insurance hero,insurance hunter,insurance in france,insurance in french,insurance in japanese,insurance initiatives ltd,insurance institute of ireland,insurance jobs ipswich,insurance jobs leeds,insurance kerala,insurance kereta,insurance malaysia,insurance meaning in urdu,insurance news net,insurance nexus,insurance nz,insurance premium tax vat,insurance protector,insurance reimbursement,insurance supermarket,insurance times,insurance underwriters uk,insurance united against dementia,insurance validity,insurance value chain,insurance winnipeg,insurance x,insurance xpress,insurance yaletownstimated the average cost of bringing a single new drug to market was $1 billion in 2000.
Tufts performed another study in 2014 and found costs were up more than 250%; the cost of introducing a new drug was nearly $2.6 billion. If you include post-approval development expenses, such as indications and dosage strength studies, the actual life-cycle cost was $2.9 billion. The study found an "intense effort by companies to increase efficiency in R&D," but those were more than offset due to the increased complexity of trials and regulatory controls.
The $3 billion it takes to introduce a drug is only the beginning. New companies need a good relationship with the FDA and the U.S. patent office to have any chance at approval. Drug patents are extremely generous, especially after the Reagan administration granted 20-year extensions in the 1980s. The limits on competition strangle innovation. Baker says this government-protected monopoly "allows drug companies to sell their drugs at prices that can be hundreds of time the free market price."
Health care and pharmaceutical costs keep rising thanks to these structural challenges and protected profits. As Game Show Network president and medical author David Goldhill explains, "Accidentally, but relentlessly, America has built a health care system with incentives that inexorably generate terrible and perverse results."
Prices Might Go Down Anyway in the Short Run
The NASDAQ Biotechnology Index fell from above 3,600 to below 2,900 between October 2015 and May 2016. This is more than a 20% decline. Angry consumers and fear of extra innovation may be key drivers of price pressure on pharmaceutical stocks.
In response, health insurers have pushed for so-called "value-based" deals to get price discounts from drug manufacturers. PricewaterhouseCoopers reported that drug prices "reached a boiling point" in the U.S. thanks to pressure from insurers and patients, and that insurance companies can use unfavorable sentiment and declining pharmaceutical equity performance to negotiate lower costs.
0 Response to "CHEESY GARLIC PARMESAN SPINACH SPAGHETTI SQUASH"
Post a Comment